Lexaria Bioscience's gross profit for the
three
months ended in Nov. 2024 was $0.18 Mil. Lexaria Bioscience's gross profit for the trailing twelve months (TTM) ended in Nov. 2024 was $0.49 Mil.
Lexaria Bioscience had a gross margin of 98.37% for the quarter that ended in Nov. 2024 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Lexaria Bioscience was 99.40%. The lowest was -100.00%. And the median was 73.91%.
Lexaria Bioscience Gross Profit Historical Data
The historical data trend for Lexaria Bioscience's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexaria Bioscience's Gross Profit
For the Biotechnology subindustry, Lexaria Bioscience's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Gross Profit distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Gross Profit falls into.
Lexaria Bioscience Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Lexaria Bioscience's Gross Profit for the fiscal year that ended in Aug. 2024 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.49 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lexaria Bioscience had a gross margin of 98.37% for the quarter that ended in Nov. 2024 => Durable competitive advantage
Lexaria Bioscience Gross Profit Related Terms
Thank you for viewing the detailed overview of Lexaria Bioscience's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEXX has been successfully added to your 